Wave Life Sciences (WVE) Net Cash Flow Growth (3y) (2017 - 2026)
Wave Life Sciences (WVE) Net Cash Flow Growth (3y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,440.76 Bn | 66,440.47 Bn | - | -50.33% |
| 2 | Nanobiotix | 1,909.20 Bn | 1,909.14 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 468.28 Bn | 463.49 Bn | 1.35 Bn | 38.47% |
| 5 | Vertex Pharmaceuticals | 122.49 Bn | 115.24 Bn | 2.59 Bn | 33.37% |
| 6 | Regeneron Pharmaceuticals | 70.26 Bn | 61.51 Bn | 3.31 Bn | -29.82% |
| 7 | Belite Bio | 62.88 Bn | 62.88 Bn | - | - |
| 8 | Argenx Se | 55.67 Bn | 50.48 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.37 Bn | 34.36 Bn | 959.66 Mn | 32.17% |
| 10 | Wave Life Sciences | 1.18 Bn | 638.40 Mn | - | -35.33% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -35.33% |
| Dec 31, 2025 | 267.18% |
| Sep 30, 2025 | 22.38% |
| Jun 30, 2025 | -36.84% |
| Mar 31, 2025 | 12.70% |
| Dec 31, 2024 | -32.52% |
| Sep 30, 2024 | 114.51% |
| Jun 30, 2024 | -78.87% |
| Mar 31, 2024 | 18.59% |
| Dec 31, 2023 | 57.26% |
| Sep 30, 2023 | -31.42% |
| Jun 30, 2023 | -9.67% |
| Mar 31, 2023 | 87.39% |
| Dec 31, 2022 | 48.30% |
| Sep 30, 2022 | 15.88% |
| Jun 30, 2022 | 55.72% |
| Mar 31, 2022 | -40.74% |
| Dec 31, 2021 | 40.11% |
| Sep 30, 2021 | 13.73% |
| Jun 30, 2021 | -26.74% |